Background. The population of long-term survivors of childhood brain tumors (BTs) is growing. The aim of our study was to evaluate late-appearing morbidity in BT survivors.
Gradually improving survival rates for childhood brain tumors (BTs) and a growing population of long-term survivors have expanded the focus of research to investigating the late outcomes of survivors. 1 Many of the earlier reports concerning morbidity of long-term childhood BT survivors have suffered from small sample sizes. 2 -5 Large studies, on the other hand, were mostly based on questionnaires and thus have possible recall bias and selection bias. 6 -10 Only a few registry-based studies have been performed. 11 -16 Earlier studies have shown high rates of cognitive impairment, 2, 6 ,17 endocrinopathy, 6, 10, 14, 17 and neurological sequelae 2, 18, 19 among childhood BT survivors. However, late-appearing morbidity has been less studied. The data on actual psychiatric diagnoses are limited and show a slightly increased risk for psychiatric hospitalization in general. 12, 16 Childhood BT survivors have an increased risk of morbidity and death due to cardiovascular/cerebrovascular disease. 8, 9, 20, 21 Kidney dysfunction among childhood cancer survivors in general has been mainly associated with potentially nephrotoxic therapy, 4, 22, 23 but research focusing on BT survivors is scarce. 4 Data concerning osteoporosis or other musculoskeletal disease have been conflicting. 5, 22 The aim of our study was to evaluate the burden of late-appearing morbidity needing specialized health care in childhood BT patients who survived 5 years or longer after cancer diagnosis with long-term follow-up.
Subjects and Methods
We identified all patients (n ¼ 1163) who had been diagnosed with a neuroepithelial BT at the age of 0 -15 years between 1970 and 2004 from the nation-wide Finnish Cancer Registry (FCR).
Morbidity was studied among those who survived at least 5 years after diagnosis (n ¼ 740). The median follow-up time after surviving for 5 years was 12.0 years (range, 0 -33 years). (Table 1) Siblings of the BT patients were identified via their common parents by linkage to the Population Register Centre using the unique identification number of each resident in Finland. The sibling cohort (n ¼ 3615 and no cancer diagnosis before age 35 years) of the original BT patient group was used as the comparison cohort.
The FCR maintains a database containing all cancers diagnosed in Finland since 1953. The FCR is estimated to have greater than 98% coverage for malignant CNS tumors, but coverage for benign CNS tumors is more constricted (80.6%). 24 The FCR contains data on patient identification, date of birth, sex, date of diagnosis, tumor morphology, primary site, malignancy, primary treatment, possible emigration date, possible date of death, and underlying cause of death. We used treatment data only on the basic level: surgical treatment (yes/no), and radiation treatment (yes/no). Chemotherapy details or doses of radiation were not systematically available. The FCR coding follows the ICD-O-3 system for topography and morphology. However, because ICD-O-3 coding was introduced in 2008 and the previous codes were converted to the new version, we checked astrocytomas and gliomas from the original notifications to be sure of the correct classification. Thereafter, the BT cases were grouped as proposed by the third edition of WHO International Classification of Diseases for Oncology 25 : astrocytic tumors, other glial tumors (oligodendroglial and oligoastrocytic tumors), ependymal tumors, embryonal tumors, other specified neuroepithelial tumors (neuronal, mixed neuronal-glial tumors, and tumors of pineal region), and brain tumors not otherwise specified (NOS). Low-grade astrocytomas in children usually need only surgical treatment. Childhood astrocytomas were included in the present analysis because low-grade astrocytomas are relatively frequent in this age group, and some survivors are known to suffer from neurological, cognitive, emotional, and endocrinological late effects. 26, 27 The National Institute for Health and Welfare collects a hospital discharge registry (HDR) that contains information on the main diagnoses of all patients treated as hospital inpatients. Information has been available in electronic form since 1975, and data from outpatient care in specialized health care units have also been registered since 1994. The register includes data on patient identification for linkage with other registers. Data are coded according to the International Classification of Diseases (ICD) format, and diagnoses coded according to older versions (ICD-8 during 1969 (ICD-8 during -1986 or ICD-9 during 1987 -1995) were manually converted to ICD-10 format prior to analyses. The completeness and accuracy of the register has been estimated to vary from satisfactory to very good, depending upon the diagnoses being studied. 28 The outcome diagnoses were divided into 8 main categories: endocrine diseases, psychiatric disorders, cognitive and developmental disorders, neurological diseases, disorders of vision/ hearing, diseases of the circulatory system, disorders of the musculoskeletal system/connective tissue, and diseases of the kidney (Table 2) . Infectious diseases were excluded, as were other diagnoses that are mainly handled in the primary health care setting.
The study protocol was approved by the Ethical Committee of the Hospital District of Southwest Finland (register number 18/180/2010, date April 20, 2010) . The permission for use of the registry data from the FCR and HDR was obtained from the National Institute for Health and Welfare (register number THL/531/5.05.00/2010, date October 12, 2010). 
Statistical Analysis
The morbidity of BT survivors was compared with that of the sibling cohort. Hazard ratios (HRs) were calculated with Cox regression, and 95% confidence intervals (95% CI) were determined. Follow-up for survivors began 5 years after diagnosis, and siblings aged 5 years and older were followed beginning January 1, 1975. Follow-up ended at the date of first hospitalization for each of the studied adverse outcomes. Subjects were censored at death, emigration, or on December 31, 2008. The HRs were analyzed separately for the main outcomes in the following subgroups: astrocytic tumors and other gliomas (grouped together), embryonal tumors, and ependymomas. Treatment eras (1970 -1979, 1980 -1989, 1990 -2004 ), birth year cohort (1959 or earlier, 1960 -1969, 1970 -1979, 1980 -1989, 1990 or after), sex, and interaction between sex and previous cancer status (survivor/sibling) were used as predictors of morbidity in order to study sex and treatment eraspecific HRs compared with siblings. Contrasts were used to compare the 3 treatment eras of survivors. The effect of radiation treatment and age at cancer diagnosis for the main outcomes were evaluated separately. These analyzes were adjusted for sex and birth-year cohort. The irradiated 5-year survivors were compared with the nonirradiated survivors, and the 5-year survivors diagnosed with a brain tumor at 6 -10 years or 11 -15 years of age were compared with those diagnosed at 0 -5 years of age.
The cumulative prevalence of 8 main outcomes among BT survivors was analyzed at 5, 10, 20, and 30 years from cancer diagnosis and compared with the outcome of the sibling cohort using the Fisher' exact test. The mean age of the survivors at each time point was used as the evaluation age of the sibling cohort. Cumulative prevalence was assessed by calculating the percentage of survivors diagnosed during each evaluation period against all survivors alive at the end of that period. The significance level of P , .05 was used. Statistical analyses were performed using SAS, version 9.3.
Results

The Survivors Versus the Siblings
The morbidity for survivors is compared with siblings in Table 3 . The HR for endocrine diseases was increased (HR, 14.7; 95% CI, 
The Effect of Sex and Treatment Era
The HRs by treatment era and sex of the survivors, compared with the siblings, are presented in Figure 1 . The female survivors showed a significantly increased HR for psychiatric disorders compared with the siblings in every treatment era studied, whereas only male survivors treated in the 1970s had an increased risk compared with the siblings. The female survivors treated in the 1970's or 1980's showed significantly increased HRs for diseases of circulatory system, whereas male survivors had no significant increase in any treatment era studied compared with the siblings. When the effect of interaction between sex and previous cancer status (survivor/sibling) on the risk of morbidity was assessed, significant association was found only for disorders of vision or hearing loss (P ¼ .046). The hazard for female survivors compared with female siblings was higher than the hazard for males. When comparing risk between different treatment eras, there was a significant difference in morbidity for disorders of vision or hearing loss between the treatment eras (P ¼ . 
The Effect of Age at Diagnosis
The age at cancer diagnosis did not have a significant effect on HRs for any of the studied late morbidities: endocrine diseases 
Irradiated Versus Nonirradiated Survivors
The irradiated survivors had a significantly increased HR for endocrine diseases (HR, 6.2; 95% CI, 3.3 -11.7), neurological diseases (HR, 1.8; 95% CI, 1.2 -2.8), and disorders of vision or hearing (HR, 2.1; 95% CI, 1.2-3.9) compared with nonirradiated survivors but not for the other main outcomes studied: psychiatric disorders (HR, 0.9; 95% CI, 0.5 -1.6), cognitive and developmental disorders (HR, 1.9; 95% CI, 0.8 -4.1), diseases of circulatory system (HR, 2.2; 95% CI, 0.8 -6.3), disorders of musculoskeletal system or connective tissue (HR, 0.9; 95% CI, 0.4 -1.8), and diseases of the kidney (HR, 3.6; 95% CI, 0.7 -19.7).
The Age-specific Cumulative Prevalence
The cumulative prevalence figures of the survivors and the siblings are shown in Table 4 . The prevalence for endocrine diseases, cognitive and developmental disorders, neurological diseases, and disorders of vision/hearing loss were high among BT survivors, and a significant difference compared with the sibling cohort persisted throughout the entire follow-up period (P , .05). The prevalence for psychiatric disorders of the survivors rose constantly during follow-up, and the difference when compared with the siblings remained significant for 20 years (P , .001). The prevalence for circulatory diseases was relatively low, but a significant difference between BT survivors and the control group could still be seen after 20 years (P , .001), while there was no difference observed for diseases of the kidney between the survivors and the siblings after 10 years.
Discussion
In the present study, we found that 5-year survivors of childhood BTs have an increased HR for late diagnosis of endocrine diseases, psychiatric disorders, cognitive and developmental disorders, disorders of vision/hearing loss, neurological diseases, and diseases of circulatory system that require treatment in specialized health care settings when compared with siblings. When the treatment era was taken into account, some changes could be seen, such as an increase in HR for endocrine diseases and vision/hearing impairments in survivors treated after the 1980s'. Female survivors had a higher hazard for disorders Gunn et al.: Morbidity in childhood brain tumors survivors of vision or hearing loss compared with female siblings than male survivors when compared with male siblings. The type of BT had some effect on HRs, but the differences were smaller than expected from differences in usual therapies. The majority of outcomes had an increasing prevalence up to 10 to 30 years after primary BT diagnosis. The results emphasize the need for systematic follow-up of these patients for many years after the end of their cancer treatment.
The HR for late-appearing endocrine diseases in our survivor cohort compared with the control group (especially for hypothyroidism, and disorders of the pituitary gland) were very high. Our study concurred with the published data from the Childhood Cancer Survivorship Study (CCSS) cohort. 6 The present study demonstrated an increase in the HR among survivors treated during recent decades. This can be explained by changes in treatment modalities leading to better survival and probably also by more systematic follow-up of survivors. We found the highest HR for endocrine diseases in survivors of embryonal tumors, which is logical considering their multimodal treatment protocols with whole brain irradiation. The prevalence of endocrinopathies among childhood cancer survivors strongly depends on their exposure to certain treatments such as radiation to hypothalamic-pituitary axis or neck, or alkylating agents. 22 At least 11% of BT survivors are known to suffer from psychological distress, 7 and even one-third may suffer from posttraumatic stress symptoms. 29 A recently published registrybased study showed that BT survivors have a greater risk for organic psychosis, neurodevelopmental disorders, emotional and behavioral disorders, as well as anxiety in male survivors leading to hospital contact. 16 In our study, the HR for psychiatric problems was increased mainly in female survivors and survivors with a history of glioma. However, the survivors' sex showed no significant effect on the outcome. The difference found in tumor histology may also be a chance finding because the numbers are small. The results of earlier studies have been discordant concerning the effect of sex on the psychological outcome of childhood BT survivors. 7, 16 The increased HR in In keeping with previous findings, 2,6,17,32 we found a significant increase in the number of cognitive defects within the survivor cohort in general. Surprisingly, neither the treatment era nor the age at diagnosis had any significant effect on the number of cognitive diagnoses in our study. The reason why ependymoma survivors did not have an increased risk for cognitive diagnoses could be explained by the survivors of grade I ependymomas being treated with surgery alone as well as the small number of ependymal tumors overall in our data. However, our finding concurs with a report by the CCSS. 6 The increase in the prevalence of cognitive and developmental disorders can be seen up to 10 years after diagnosis, which is logical because it is believed that decline in cognitive performance after childhood CNS tumor is a result of failure to keep up in development rather than loss of previous skills. 33 Our prevalence figures seem low, while other studies have shown that only 48% -66% of childhood BT survivors had a normal IQ and that 58% -68% were able to attend school with no need for special help. 2, 17 This may reflect the situation that not all survivors with cognitive difficulties had proper testing and might have never been diagnosed with impaired cognition, even though they would fulfill the criteria. There might also be differences in study populations. In our study, where only 5-year survivors were included, one-third of the survivors had received irradiation, while the figure might be close to 70% in other studies. 6, 17 The survivors were more likely to have neurological diseases. However, no significant differences between sex and treatment era were seen. Almost 70% of BT survivors may suffer from some abnormality in their neurological status. 2 In this study, however, only symptoms fulfilling diagnostic criteria were assessed. Other studies have shown 21% -25% of survivors having seizures and approximately one-half having some motor/coordination impairment at least 5 years after diagnosis. 18, 19 Our results for disorders of vision/hearing loss were similar to other studies. 2, 6, 17 For sensory problems altogether, the HR was higher for females and later treatment eras because the numbers of long-term survivors have increased due to multimodal therapies. To the best of our knowledge, a greater risk for sensory problems in female survivors compared to male survivors has not been shown previously.
The increased risk in our study for diseases of the cardiovascular system was mainly caused by an increase in vascular diseases of brain. Earlier studies have likewise shown that BT survivors have an increased risk for late-occurring strokes 9 as well as an increased risk for dyslipidemia and high blood pressure. 3 In one study, early-onset BT survivors reported congestive heart failure, myocardial infarction, and pericardial disease more often than their siblings. 8 In our study cohort, the hospital discharge register indicated only one case of ischemic heart disease and one case of cardiomyopathy/heart failure among the survivors more than 5 years after the BT. Signs of worse cardiac outcomes have been reported in other studies (especially increased myocardial stress) among female childhood cancer survivors. 8, 34 Although our study showed an Table 4 . The mean age of the survivors at each time point is used as the age of evaluation for the sibling cohort.
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increased HR for diseases of the circulatory system for female survivors only, there was no significant difference in hazard between the sexes; thus, our results imply that sex has only a minor, if any, influence on circulatory health of the survivors. A previous study found a prevalence as high as 33% for low bone density with childhood BT patients. 5 Another study, which included survivors of all childhood cancer types, reported only a 9.6% prevalence of osteoporosis for those exposed to potentially harmful treatment. 22 The relatively low risk for musculoskeletal morbidity in our study may reflect insufficient screening for low bone density among BT survivors with no previous fractures or missing information because no hospitalization was needed.
The risk for impaired kidney function in pediatric BT survivors is poorly described. One study with a short follow-up found glomerular dysfunction in almost one-third of survivors who had received cisplatin. 4 Two large studies on all childhood cancer survivors had only a small proportion of BT survivors. 22, 23 One of these found that survivors exposed to high-risk treatment had a 5.0% prevalence of kidney dysfunction, while unexposed survivors had a prevalence of 1.6%. 22 Another study showed similar results: the probability for glomerular dysfunction for survivors with and without nephrotoxic therapy was 5.4% and 1.7%, respectively, at 15 years after diagnosis. 23 Our study showed an increased HR for diseases of the kidney only for survivors with embryonal tumors compared with siblings. Nephrotoxic chemotherapy had become more commonly used just after the mid 1990's; thus, the follow-up time is still short and may affect the results.
Notable in the present study was that irradiated survivors had an increased HR compared with nonirradiated survivors only for late-appearing endocrine diseases, neurological diseases, and disorders of vision/hearing but not for late psychiatric disorders or cognitive and developmental disorders. The age at cancer diagnosis had no effect on any of the main outcomes either. The increased age limit for irradiation from mid 1990s may have reduced the risk for cognitive disorders. On the other hand, the present study examined late morbidity, and many of the cognitive diagnoses may occur earlier.
Limitations
A registry-based study offers objective data on the morbidity of former patients even long after cancer diagnosis. Unfortunately, the registry data used in the present study do not include diagnoses outside of hospitals (eg, primary health care setting) nor offer the opportunity to analyze the impact of precise treatment modalities. There are also some limitations concerning the HDR data. Old HDR data may have missed some diagnoses because the focus was on the main cause for hospitalization. However, the control group of siblings shares the same problem. Some diseases are primarily diagnosed and/or treated in general health care settings and thus were not registered into HDR. We tried to exclude these kinds of diagnoses from the analyses to minimize this shortcoming. Most pediatric diseases (eg, all endocrinological problems except for obesity) in Finland are treated in specialized health care settings and thus should be registered in the HDR. Childhood BT survivors are followed at university hospital clinics for a variable time period depending on tumor histology and the treatment given. However, the follow-up of adult survivors might be moved to a general health care setting, and some diagnoses made outside of hospitals may be underestimated here (eg, hypothyreosis and mild psychiatric disorders). No structured follow-up clinics, which would search specifically for very late-emerging adverse effects, have been established in Finland to date. For BT survivors, however, some diagnoses are also actively searched for during the early years of follow-up causing a potential for a bias, shared also by the self-report based studies. Siblings of the survivors were used as the control cohort in the present study in order to highlight the effect of cancer and diminish the bias from genetic susceptibility and variability in psychosocial background on morbidity. Another limitation of the present study is the lack of information about the details of chemotherapy treatment that might increase the risk for certain late-effects in childhood cancer survivors such as strokes, certain cardiac problems, cataracts, and several auditory problems. 9, 10, 35, 36 On the other hand, not all studies have been able to confirm these results. 18 
Conclusions
In the present study, we analyzed late morbidity of childhood BT patients who survived at least 5 years after diagnosis. By now, most of the late-outcome studies with a sufficiently large cohort of this specific group have been obtained from the extensive CCSS cohort. However, results from CCSS cohorts must be confirmed with analyses from other study cohorts so that future recommendations for long-term follow-up would be based on the most comprehensive data. Because the structure of societies and the way health care is organized differ even in the Western countries, it cannot be taken for granted that the results of the CCSS cohort can be generalized elsewhere. The present study introduces the results from a nationwide cohort of one European country that mainly confirms the results of CCSS. Our study showed that most of the main outcomes had a high prevalence even 10 to 30 years after primary BT diagnosis. Milder cognitive deficits may partly explain the late psychiatric and neurological morbidity of BT survivors. Today, we have a vast selection of tools for identifying milder risks for neuropsychological deficits, which may lead to better cognitive outcome and better quality of life later. Minimizing the risk of social exclusion should be the key target of a follow-up procedure for BT survivors. Organizing systematic comprehensive and multidisciplinary follow-up for long-term survivors is essential, and we feel the information gathered in the present study will support this process. 
